Arana Therapeutics
107 search results

Arana Therapeutics Limited, formerly Peptech Limited, is engaged in the commercialization of research, development, investment in and licensing of technology, and the formulation, manufacture and marketing of protein-based products for the pharmaceutical and veterinary industries. It is engaged in the development of lead compounds directed at the anti-inflammatory biologics market. ART621 for rheumatoid arthritis (RA) is a domain antibody-based compound that targets a protein called tumor necrosis factor (TNF), that plays an important role in the development of rheumatoid arthritis (RA) and other autoimmune diseases. PMX53 is a small cyclic peptide in the preclinical phase of development. ART010 for osteoporosis and bone cancer. ART150) for lung cancer and ART104 for solid tumors. Some of its subsidiaries include EvoGenix Pty Ltd, EvoGenix Inc, Peptech Animal Health Pty Ltd and Peptech Investments Pty Ltd. On August 28, 2007, the Company acquired 100% of EvoGenix Limited.

Address: Level 2, 37 Epping Road, MACQUARIE PARK, NSW, AUSTRALIA, 2113

Phone: 02 8061 9900
Fax: 02 8061 9999